Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Rivaroxaban in Acute Ischemic Stroke/TIA with AF
NCT03749057Phase 4Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Nov 2018
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in ischemic stroke, Transient Ischemic Attack (TIA) and Atrial fibrillation (AFib), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Incidence of Intracranial Hemorrhage at 7 days. Started Nov 2018; status: completed.
02
Drugs
rivaroxaban
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03749057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749057.